August 2024
The global liposome drug delivery market size surpassed USD 5.13 billion in 2023 and is estimated to increase from USD 5.59 billion in 2024 to approximately USD 13.12 billion by 2034. It is projected to grow at a CAGR of 8.91% from 2024 to 2034.
The global liposome drug delivery market size is expected to be worth USD 5.59 billion in 2024 and is anticipated to reach around USD 13.12 billion by 2034, growing at a CAGR of 8.91% over the forecast period 2024 to 2034. The rising healthcare infrastructure and the increasing use of liposome drug delivery method in the various disease such as cancer, skin infraction and other infectious disease are driving the growth of the market.
The U.S. liposome drug delivery market size was exhibited at USD 1.58 billion in 2023 and is projected to be worth around USD 4.11 billion by 2034, poised to grow at a CAGR of 9.07% from 2024 to 2034.
North America dominated the liposome drug delivery market in 2023. The growth of the market is attributed to the rising advancement in the healthcare and pharmaceutical sectors, and the support of government facilities and policies towards medical infrastructure drives the growth of the healthcare sector. The rising burden of cancer cases in the United States and Canada is driving the demand for precise oncology treatment, which boosts the growth of liposome drug delivery and other oncology drugs and delivery systems. Additionally, the availability of major healthcare providers and medical technology leaders is also driving the expansion of the liposome drug delivery market across the region.
Asia Pacific is anticipated to grow at the fastest rate during the forecast period. The growth of the market is attributed to the rising population and the increasing availability of the geriatric population, which is more likely to get affected by cancer and another chronic diseases that drives the demand for liposome drug delivery for efficient treatment procedures in patients that contribute in the growth of the liposome drug delivery market in the region.
Liposomes are known for their carrier of the nanocarrier for the potentially active hydrophilic and hydrophobic due to their higher biodegradability, biocompatibility, and low immunogenicity. The liposomes are efficiently used in increasing drug solubility, controlled distribution, and capacity for surface modifications for prolonged, targeted, and sustained release. Liposome drug delivery is used for the treatment of several diseases, such as fungal infections, cancer, viral infections, and others. It minimizes the side effects of the drugs and residence time in target cells. The rising cases of chronic illness in the population are driving the demands for the liposome drug delivery market.
How Can AI Impact the Liposome Drug Delivery Market?
Artificial intelligence transforms the various sectors and their operations. The adaptation of AI in the healthcare sector transforms the overall healthcare, pharmaceutical, and biotechnology fields. It provides powerful insights into biotechnology, including predictive modeling, data analytics, and process optimization. AI enhances healthcare operations from drug discovery to personalized diagnosis and medicine. AI works to accelerate drug discovery by optimizing drug formulations, predicting the biological activity of compounds, and identifying potential side effects. The integration enhanced the efficiency of the drug discovery process and drove the research and development process in biotechnology, helping to drive innovations in the healthcare sector.
Report Coverage | Details |
Market Size by 2034 | USD 13.12 Billion |
Market Size in 2023 | USD 5.13 Billion |
Market Size in 2024 | USD 5.59 Billion |
Market Growth Rate from 2024 to 2034 | CAGR of 8.91% |
Largest Market | North America |
Base Year | 2023 |
Forecast Period | 2024 to 2034 |
Segments Covered | Liposome Structure, Product, Technology, Application, End-User, and Regions |
Regions Covered | North America, Europe, Asia-Pacific, Latin America and Middle East & Africa |
The rising adoption of liposome drugs for skin
The rising younger population and the rising awareness of skincare are driving the demand for active chemicals that help rejuvenate skin and enhance the skincare process. Where liposomes are small spherical shapes that help in skin care and reduce the side effects of cosmetics products. Liposome delivery is the method of cosmetic formulation. The liposome's properties, such as penetration, stability, and effectiveness of active substances, enhanced the quality and effectivity of the product. Liposomes are used in a variety of skincare owing to their distinct structure. Its higher encapsulation properties benefit the skincare, increase the penetration into the skin, and increase efficiency.
High cost
The increased cost of treatment, the possibility of instability, poor manufacturing process, and increased intracellular delivery are some of the associated limitations on the growth of the liposome drug delivery market.
The increase in demand for advanced drugs and treatment procedures
The increasing prevalence of chronic diseases and the rising demand for precise drug delivery methods for better treatment drive the growth opportunity for the liposome drug delivery market. The rising adaptation of the modern drug delivery procedure with reduced side effects and unparalleled accuracy in the treatment procedures. Liposomes have unique properties like encapsulation within the bilayer structure, which works as the shield of the drugs from degradation. Liposomes are highly effective for targeting tissues or specific cells.
The unilamellar liposomes segment dominated the liposome drug delivery market in 2023. The increased adoption of the unilamellar liposome in oncology treatment is owing to its higher accuracy in the format of dosage; its single-layer lipid transforms the drug administration process by encapsulating pharmaceutical agents with accuracy. They are mostly used in the study of biological systems and mimic cell membranes. The unilamellar liposome is divided into three parts that are small unilamellar liposomes/vesicles (SUVs) with a 20–100 nm size range, giant unilamellar liposomes/vesicles (GUVs) with a 1–200 μm size range, and large unilamellar liposomes/vesicles (LUVs) with a 100–1000 nm size range. The unilamellar liposomes are highly used in medical studies and are used to provide tools for studying protein localization in the plasma membrane, membrane fusion, study ion channels, etc.
The liposomal doxorubicin segment held a dominant presence in the liposome drug delivery market in 2023. The liposomal doxorubicin is also known as the Caelyx; it is the type of chemotherapy that is used in the treatment procedure of the patient with cancer disease. It is a chemotherapy drug known as the anthracycline.
It is used in cancer treatment to restrict the expansion of the enzyme named topoisomerase 2, which helps in the expansion of the cancer cells. It contained tiny spheres called pegylated liposomes. The rising cases of cancer patients worldwide are driving the demand for treatment and chemotherapy, which boosts the demand for liposomal doxorubicin.
The stealth liposome technology segment accounted for a considerable share of the liposome drug delivery market in 2023. The Stealth liposome technology is the revolution in pharmaceutical operations and in the treatment procedures related to oncology. The stealth liposome excels in evading immune detection, incorporating polyethylene glycol (PEG) coatings, extending circulation, and increasing drug targeting is reshaping the oncology treatment procedures. The stealth liposome technology helps in enhancing the personalized medicine trajectory and enhances medicinal efficiency, patient-centric treatment, and targeted therapies.
The cancer therapy segment registered its dominance over the global liposome drug delivery market in 2023. Liposome drugs are highly beneficial in the treatment of cancer; they directly target cancer cells with greater precision with lower side effects. They are used in the treatment by delivering drugs through chemotherapy. The global rise in cancer patients and the disease being the second leading cause of death and expanding as the major health issue in the population drives the demand for an efficient cancer diagnostics process. There are several types of cancer found worldwide. The changing lifestyle preferences, environmental issues, and genetics are the major causes of cancer. The rising investment in cancer drug development drives the demand for liposome drug delivery.
The hospitals segment dominated the liposome drug delivery market in 2023. The increasing preference for getting proper diagnostics and treatment of several kinds of diseases in the hospitals due to the higher availability of skilled and professional healthcare workers and healthcare infrastructure such as medical devices and drugs boosts the preference of the hospital segment. Hospitals are pursuing rising investment in the healthcare infrastructure and technological advancements to enhance the efficiency of healthcare operations.
Segments Covered in the Report
By Liposome Structure
By Product
By Technology
By Application
By End-User
By Geography
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
August 2024
June 2023
October 2023
May 2023